Ruthenium-Catalyzed Conversion of sp3 C–O Bonds in Ethers to C–C Bonds Using Triarylboroxines
摘要:
Catalytic conversion of unreactive sp(3) C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.
Ruthenium-Catalyzed Conversion of sp3 C–O Bonds in Ethers to C–C Bonds Using Triarylboroxines
摘要:
Catalytic conversion of unreactive sp(3) C-O bonds in alkyl ethers to C-C bonds is described. Alkyl ethers bearing 2- or 4-pyridyl groups were coupled with triarylboroxines in the presence of a ruthenium catalyst. Triarylboroxines bearing a variety of functional groups including electron-withdrawing and -donating groups can be used for the reaction. No additional base was required for the coupling with the organoboron reagents, and base-sensitive groups can be tolerated. The reaction is considered to proceed via dehydroalkoxylation followed by addition of triarylboroxines to form C-C bonds.
The present invention relates to a compound of Formula (I) and the manufacturing method(s) thereof and the use thereof:
Formula (I)
wherein: Ar is a nitrogen-containing heteroaromatic ring group; X and Z are each a carbon atom, and so on; Y is CO, and so on; R
1
is a hydrogen atom, and so on; R
2
and R
3
are each a hydrogen atom, and so on; R
4
and R
5
are each a hydrogen atom, and so on; and the formula
is a single bond or a double bond.
According to the present invention, the compound of the present invention can provide Cdk4 and/or Cdk6 inhibitors for treating malignant tumors, because the compounds of the present invention exhibit a prominent growth inhibitory activity against tumor cells.